Atlanta Genitourinary Cancers Summit

Atlanta, GA US
March 15, 2025

The CME-accredited Atlanta Genitourinary Cancers Summit offers a multi-format educational experience focused on the latest advances in GU oncology, covering prostate, kidney, bladder, and rare cancers. Available as a live conference on March 15, 2025, a recorded webcast, and an interactive gamified activity, the summit is designed for oncologists, fellows, and other healthcare professionals. Through expert-led sessions, attendees will gain evidence-based insights into emerging treatments, guideline updates, and practical strategies via case-based discussions. The summit emphasizes personalized, patient-centered care, equipping practitioners with enhanced skills to improve outcomes and address disparities in cancer care across different learning formats.

Target Audience

  • Medical Oncologists

  • Surgical Oncologists

  • Radiation Oncologists

  • Oncology Fellows/Residents

  • Oncology Nurses

  • Nurse Practitioners

  • Physician Assistants

  • Oncology Pharmacists

Organizing Committee

Course Director:

Dr. Binay Shah - Binaytara Foundation

Conference Chairs:

Dr. Mehmet Asim Bilen - Emory University

Dr. Yousef Zakharia - Mayo Clinic

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review current standards and evolving strategies for the management of both localized and advanced genitourinary malignancies.
  • Incorporate practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with genitourinary cancers.
  • Select treatment plans based on patient and disease factors.
  • Compare and contrast the safety and efficacy profiles of various therapeutic strategies to enhance decision-making in the management of patients with genitourinary cancers
Course summary
Available credit: 
  • 6.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.
Course opens: 
09/06/2024
Course expires: 
07/15/2025
Event starts: 
03/15/2025 - 8:00am PDT
Event ends: 
03/15/2025 - 4:00pm PDT
Cost:
$350.00

March 15th, 2025

All times set in Eastern Daylight Time (EDT)

07:00 AM – 08:00 AM  Breakfast, Registration, & Exhibits


08:00 AM – 08:05 AM  Welcome

08:05 AM – 08:30 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA


08:30 AM – 10:00 AM  Session 1: Prostate Cancer

Session Chair: Bradley Carthon, MD

08:30 AM – 08:50 AM  Current Treatment Landscape for mHSPC - Chandler Park, MD

08:50 AM – 09:10 AM  Treatment Updates in mCRPC - Rohan Garje, MD

09:10 AM – 10:00 AM  Case-Based Discussion - Jordan Ciuro, MD


10:00 AM – 10:30 AM  Break & Exhibits


10:30 AM – 12:00 PM  Session 2: Kidney Cancer

Session Chair: Mehmet Asim Bilen, MD

10:30 AM – 10:50 AM  Evolving Landscape of Treatment for First Line mRCC - Pedro Barata, MD, MSc, FACP

10:50 AM – 11:10 AM  Current and Emerging Treatments in Non-Clear Cell RCC and Subsequent Line Advanced Clear-Cell RCC - Benjamin Maughan, MD, PharmD

11:10 AM – 12:00 PM  Case-Based Discussion - Shahid Ahmed, MD, MBBS


12:00 PM – 01:00 PM  Lunch & Exhibits


01:00 PM – 02:30 PM  Session 3: Bladder Cancer

Session Chair: Shreyas Joshi, MD, MPH

01:00 PM – 01:20 PM  Guideline Recommended Care in mUC - Rohit Jain, MD

01:20 PM – 01:40 PM  Emerging Treatment Options for MIBC - Arnab Basu, MD, MPH, FACP

01:40 PM – 02:30 PM  Case-Based Discussion - Jacqueline Brown, MD


02:30 PM – 03:00 PM  Break & Exhibits


03:00 PM – 04:30 PM  Session 4: Rare Tumors

Session Chair: Vikram Narayan, MD

03:00 PM – 03:20 PM  Management of Penile Cancer - Viraj Master, MD, PhD, FACS

03:20 PM – 03:40 PM  Novel Treatment Approaches for ACC - Matt Campbell, MD, MS

03:40 PM – 04:30 PM  Case-Based Discussion - Bassel Nazha, MD, MPH


04:30 PM  Adjourn

Grand Hyatt Atlanta
3300 Peachtree St NE
Atlanta, GA 30305
United States

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

Conference Chair(s)

Mehmet Bilen, MD

has a financial relationship (Other) with Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen, and Sanofi ;.
has a financial relationship (Grant Or Contract) with Merck, Xencor, Bayer, Bristol-Myers Squibb, Genentech/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Exelixis, Nikang, Loxo Oncology, Ambrx, Regeneron, Acrivon Therapeutics, Amgen, Genome & Company, AAA, Peloton Therapeutics, Pfizer;.

Yousef Zakharia, MD

has a financial relationship (Professional Services) with Eisai ;.
has a financial relationship (Professional Services) with Exelixis;.
has a financial relationship (Professional Services) with Gilead ;.
has a financial relationship (Professional Services) with Seagen ;.
has a financial relationship (Professional Services) with Janssen;.
Session Chair(s)

Mehmet Bilen, MD

has a financial relationship (Other) with Exelixis, Bayer, BMS, Eisai, Pfizer, AstraZeneca, Janssen, Calithera Biosciences, Genomic Health, Nektar, EMD Serono, SeaGen, and Sanofi ;.
has a financial relationship (Grant Or Contract) with Merck, Xencor, Bayer, Bristol-Myers Squibb, Genentech/Roche, SeaGen, Incyte, Nektar, AstraZeneca, Tricon Pharmaceuticals, Exelixis, Nikang, Loxo Oncology, Ambrx, Regeneron, Acrivon Therapeutics, Amgen, Genome & Company, AAA, Peloton Therapeutics, Pfizer;.

Shreyas Joshi

has a financial relationship (Professional Services) with Engene;.
has a financial relationship (Professional Services) with CG Oncology;.
has a financial relationship (Professional Services) with Photocure;.
has a financial relationship (Professional Services) with Blue Earth Diagnostics;.

Yousef Zakharia, MD

has a financial relationship (Professional Services) with Exelixis;.
has a financial relationship (Professional Services) with Gilead ;.
has a financial relationship (Professional Services) with Seagen ;.
has a financial relationship (Professional Services) with Janssen;.
has a financial relationship (Professional Services) with Eisai ;.
Speaker/Topic Presenter(s)

Pedro Barata, MD, MSc, FACP

has a financial relationship (Professional Services) with Eisai;.
has a financial relationship (Professional Services) with Bayer;.
has a financial relationship (Professional Services) with Merck;.
has a financial relationship (Professional Services) with BMS;.
has a financial relationship (Professional Services) with Pfizer;.
has a financial relationship (Professional Services) with AStellas ;.
has a financial relationship (Professional Services) with Ipsen;.
has a financial relationship (Professional Services) with AstraZeneca;.
has a financial relationship (Professional Services) with Caris Life Sciences;.
has a financial relationship (Professional Services) with Aveo Oncology;.

Arnab Basu, MD, MPH

has a financial relationship (Independent contractor) with Eisai;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Arcus;.
has a financial relationship (Independent contractor) with Exelixis;.
has a financial relationship (Independent contractor) with EMD Serono;.

Matthew Campbell, MD, MS

has a financial relationship (Independent contractor) with Dava Oncology;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Curio Sciences;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Independent contractor) with Eisai;.
has a financial relationship (Independent contractor) with Exelixis;.
has a financial relationship (Grant Or Contract) with Janssen;.
has a financial relationship (Independent contractor) with MJH Life Sciences;.
has a financial relationship (Grant Or Contract) with Exelixis;.
has a financial relationship (Independent contractor) with SeaGen;.

Benjamin Maughan, M.D., PharmD

has a financial relationship (Independent contractor) with AVEO Oncology;.
has a financial relationship (Independent contractor) with Clovis;.
has a financial relationship (Independent contractor) with Bayer Oncology;.
has a financial relationship (Independent contractor) with Telix;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Bristol-Myers Squibb;.
has a financial relationship (Independent contractor) with Exelixis;.
has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Independent contractor) with Abbvie;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Lilly;.
has a financial relationship (Independent contractor) with NCCN;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Tempus;.
has a financial relationship (Independent contractor) with Peloton Therapeutis;.
has a financial relationship (Independent contractor) with Xencor;.

Chandler Park, Medical Doctor, Masters in Science

has a financial relationship (Grant Or Contract) with Astellas;.
has a financial relationship (Grant Or Contract) with Exelexis;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Bristol Myers Squibb;.
has a financial relationship (Grant Or Contract) with Janssen ;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Grant Or Contract) with Gilead;.
has a financial relationship (Grant Or Contract) with Aveo;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with Roche;.
Case Presenter(s)

Shahid Ahmed

has no relevant financial relationships to disclose at this time.

Jordan Ciuro, MD

has no relevant financial relationships to disclose at this time.

Bassel Nazha, MD, MPH

has a financial relationship (Professional Services) with Cardinal Health;.
has a financial relationship (Professional Services) with ntrinsiQ Specialty Solutions;.
has a financial relationship (Professional Services) with Exelixis;.
has a financial relationship (Professional Services) with Neogenomics;.
has a financial relationship (Professional Services) with Intellisphere;.

Acknowledgement of Commercial Support

This activity is supported with an Independent Medical Education Grant from:

  • Pfizer

Available Credit

  • 6.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.